Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-091130
Filing Date
2025-06-27
Accepted
2025-06-27 18:42:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5210
  Complete submission text file 0000950170-25-091130.txt   7139
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Subject) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-95001 | Film No.: 251088375
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 2F, JBUILDING, EONJU-RO 71-GIL GANGNAM-GU SEOUL Korea, Republic of 06226
Business Address 2F, JBUILDING, EONJU-RO 71-GIL GANGNAM-GU SEOUL Korea, Republic of 06226 82-10-4392-9388
KH Feelux Co., Ltd (Filed by) CIK: 0002068957 (see all company filings)

EIN.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231
Type: SCHEDULE 13G